Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Management
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Amplia's Pipeline
Amplia's Cancer Program
Amplia's Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentation
Coverage
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Recent Posts
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Meet the CEO | Dr Chris Burns
ACCENT Trial Recruitment Progress
AMP886 Activity in Acute Myeloid Leukemia (AML)
Stockhead Investor Guide
Archives
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
December 2021
November 2021
October 2021
September 2021
July 2021
June 2021
March 2021
Categories
Company News
Media
Uncategorized
Videos
December 8th, 2022
Meet the CEO | Dr Chris Burns
Read More
November 29th, 2022
ACCENT Trial Recruitment Progress
Read More
October 3rd, 2022
AMP886 Activity in Acute Myeloid Leukemia (AML)
Read More
August 18th, 2022
MEDIA RELEASE | Australian-made treatment for pancreatic cancer – clinical trial milestone
Read More
August 2nd, 2022
First patient recruited into ACCENT trial
Read More
July 28th, 2022
QUARTERLY REPORT & 4C
Read More
June 23rd, 2022
Navigating human research ethics
Read More
April 19th, 2022
QUARTERLY ACTIVITIES REPORT & 4C
Read More
March 30th, 2022
Amplia is hiring
Read More
February 17th, 2022
Improving Pancreatic Cancer Survival Rates
Read More
February 11th, 2022
WOMEN IN SCIENCE | Rhiannon Jones, Director, Operations
Read More
January 24th, 2022
Quarterly Report & 4C
Read More
December 2nd, 2021
$2.1M R&D Cash Flow Loan
Read More
November 17th, 2021
New Phase 1 Clinical Trial Data
Read More
November 8th, 2021
$12.4m Capital Raise
Read More
October 26th, 2021
Amplia appoints leading drug developer as Oncology Clinical Advisor
Read More
September 30th, 2021
New FAK research published in Science Advances
Read More
September 27th, 2021
Proactive Lifesciences Webinar
Read More
July 26th, 2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
Read More
1
